Improved synergic antidiabetic compositions

FIELD: pharmacology.

SUBSTANCE: composition comprising inulin with a degree of polymerization (DP) below about 25, and a sulfonylurea and/or a derivative thereof, or a combination thereof, wherein the composition is synergic when used to treat or delay the onset of type 2 diabetes, and wherein the composition contains 5 mg to 50 g of inulin and 0.5 mg to 2000 mg of sulfonylurea and/or a derivative thereof, or a combination thereof. A method for treatment or delaying of the onset of type 2 diabetes. A method for treatment of hyperglycemia associated with type 2 diabetes. A method for prevention of development or alleviation of a side effect in a subject having type 2 diabetes treated with sulfonylurea and/or a derivative thereof or a combination thereof, wherein the side effect arises or is aggravated by treatment with sulfonylurea and/or a derivative thereof or a combination thereof. A method for prevention of development or alleviation of a pathological condition in a subject having type 2 diabetes or hyperglycemia associated with type 2 diabetes. A method for treatment or delaying of the onset of type 2 diabetes or treatment of hyperglycemia in a subject with type 2 diabetes.

EFFECT: composition is effective for treatment or delaying of the onset of type 2 diabetes and acts synergistically.

22 cl, 13 dwg, 13 tbl, 12 ex

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: integrated resort treatment is conducted. A patient takes carbonic sodium chloride mineral water. The mineral water is heated to a temperature of 37°C before use and taken at 3 ml per 1 kg of body weight 3 times a day 40 minutes before meals. The therapeutic course makes 18 days. The patient also takes "dry" carbon dioxide baths with the CO2 concentration of 1.2-1.4 g/l at the water temperature of 35°C. The water temperature is reduced to 32°C by the end of the course. The procedure length is 15-20 minutes. CO2 is supplied from a balloon into a special box compartment at a rate of 15-20 l/min. The gas mix temperature ranges from 28°C to 38°C. The procedures are performed every second day. The course of 8-10 procedures is required.

EFFECT: method provides normalising the complete blood count, blood sugar, common urine analysis, improving the visual analysis health, renal blood flow, ophthalmic parameters by the integrated intake of mineral water and dry carbon dioxide baths, optimum regimen and length of the therapeutic course.

1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology, specifically to novel analogues of a glucagon-like peptide, and can be used in medicine to activate insulin expression in mammals and to treat sugar diabetes.

EFFECT: obtained peptide derivatives have a peptide imitating linker and provide prolonged action when treating diabetes and other diseases associated with insulinotropic peptides, gastrointestinal functions and glucagon levels.

25 cl, 23 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to pharmaceutical composition, which contains compound of insulin in concentration, sufficient for supplying therapeutically effective level of insulin compound in blood plasma for at least 3 days. Insulin compound relates to pro-medical compound, which represents insulin conjugate with linker, bound with hydrogel carrier. Also described is suspension, containing pharmaceutical composition of insulin conjugate, method of suspension obtaining, set, including pharmaceutical composition of insulin conjugate and container for introduction of composition.

EFFECT: pharmaceutical composition of insulin conjugate by invention is characterised by the fact that it has pharmacokinetic profile in vivo in fact without release of insulin compound.

26 cl, 9 dwg, 21 ex

FIELD: medicine.

SUBSTANCE: correcting cognitive disorders in the patients suffering arterial hypertension accompanying type 2 diabetes mellitus is ensured by combining a standard drug therapy with administering the preparation Kudesan 60 mg a day throughout two months.

EFFECT: administering Kudesan in the above dose and regimen provides the effective correction of cognitive disorders in the above group of patients in a combination with improving the cardiovascular function and metabolic processes.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: correcting increased levels of anxiety and depression in the patients with arterial hypertension accompanying type 2 diabetes mellitus is ensured by combining a standard drug treatment and administering Kudesan 60 mg a day for two months.

EFFECT: method provides the effective correction of anxiodepressive conditions in the given category of patients that in turn enables normalising blood pressure more effectively by reducing the negative psychosomatic effect.

1 ex, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to methods of treating type 2 diabetes, insulin resistance, insulin hyposecretion, obesity, hyperglycaemia and hyperinsulinemia, involving administering an effective amount of an anti-IL-1β antibody or its fragment into an individual, as well as to using the anti-IL-1β antibody or its fragment in preparing a composition applicable for treating the above diseases or conditions.

EFFECT: group of inventions is effective in treating type 2 diabetes mellitus, insulin resistance, insulin hyposecretion, obesity, hyperglycaemia and hyperinsulinemia.

67 cl, 13 dwg, 5 tbl, 14 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel N-containing heteroaryl derivatives of formula I or II or their pharmaceutically acceptable salts, which possess properties of JAK kinase, in particular JAK3, and can be applied for treating such diseases as asthma and chronic obstructive pulmonary disease (COPD). In formulae A represents carbon and B represents nitrogen or A represents nitrogen and B represents carbon; W represents CH or N; R1 and R2, independently represent hydrogen, C1-4alkyl, halogenC1-4alkyl, -CN; R3 represents C1-4alkyl, R9-C1-4alkyl, Cy1, where Cy1 is optionally substituted with one or several substituents R10; R4 represents hydrogen, C1-4alkyl, R12R7N-C0alkyl, where one of R7 and R12 represents hydrogen, and the other represents C1-4alkyl or group R13, which is selected from C1-5alkyl, Cy2-C0alkyl; R5 represents hydrogen; R6 represents hydrogen, C1-4alkyl, C1-4alkoxyC1-4alkyl, hydroxyC1-4alkyl, R12R7N-C1-4alkyl, R16CO-C0alkyl, Cy1; R7 represents hydrogen or C1-4alkyl; R9 represents halogen, -CN, -CONR7R12, -COR13, CO2R12, -OR12, -SO2R13, -SO2NR7R12, -NR7R12, -NR7COR12; R10 represents C1-4alkyl or R9-C0-4alkyl; R11 represents C1-4alkyl, halogen, -CN, -NR7R14; R12 represents hydrogen or R13; R13 represents C1-5alkyl, hydroxyC1-4alkyl, cyanoC1-4alkyl, Cy2-C0alkyl or R14R7N-C1-4alkyl; where Cy2 is optionally substituted with one or several constituents R11; R14 represents hydrogen or C1-4alkyl; R16 represents C1-4alkyl, halogenC1-4alkyl, C1-4alkoxyC1-4alkyl, hydroxyC1-4alkyl or cyanoC1-4alkyl; Cy1 represents monocyclic carbocyclic unsaturated or saturated ring, selected from C3-C6cycloalkyl, phenyl, or saturated monocyclic 4-6-membered heterocyclic ring, containing from 1 to 2 heteroatoms, selected from N and S, or partially unsaturated 10-membered bicyclic heterocyclic ring, containing oxygen atom as heteroatom, which can be substituted with group R11, where said ring is bound with the remaining part of molecule via any available C atom, and where one or several ring C or S atoms are optionally oxidised with formation of CO or SO2; and Cy2 represents monocyclic carbocyclic unsaturated ring, selected from C3-C6cycloalkyl, or aromatic monocyclic 4-6-membered heterocyclic ring, containing from 1 to 2 heteroatoms, selected from N and S, or unsaturated 10-membered bicyclic heterocyclic ring, containing oxygen atom as heteroatom, which can be substituted with group R11, where said ring is bound with the remaining part of molecule via any available atom C or N.

EFFECT: obtaining novel heteroaryl derivatives.

27 cl, 41 ex

Transdermal plaster // 2553350

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine. Described is matrix layer, suitable for application in plaster for transdermal delivery, aimed at introduction of biologically active compounds, which includes phosphate compound of tocopherol and polymer carrier. Also described is transdermal plaster and method of its production.

EFFECT: plaster makes it possible to efficiency introduce biologically active compounds.

48 cl, 15 tbl, 13 dwg, 12 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and represents clinical nutrition for prevention, treatment or relief of one or several symptoms, associated with impairment of metabolism or its disorder, which contains composition of polysaccharide high-viscosity dietary fibre, including viscous fibre mixture or its complex, consisting of from 48% to 90% in wt % of glucomannan, from 5 to 20 % in wt % of xanthan gum and from 5% to 30% in wt % of alginate, as well as, at least, one macroelement, selected from the group, consisting of protein carbohydrate and fat, where clinical nutrition is composed in order to provide dose of composition of polysaccharide high-viscosity dietary fibre from 20 g/day to 35 g/day for time period, effective for prevention, treatment and relief of one or several symptoms, associated with impairment of metabolism or its disorder.

EFFECT: invention ensures extension of arsenal of means, preventing, relieving or treating one or several symptoms, associated with impairment of metabolism or metabolic disease.

14 cl, 6 ex, 20 tbl, 48 dwg

FIELD: medicine.

SUBSTANCE: patients with diabetic microangiopathy are subjected to an examination which includes: general blood test, blood sugar, general urine analysis, ultrasonic examination of kidneys with the determination of indices of the kidney blood flow (Vmax, Vmin, S/D, PI, RI), basic ophthalmological parameters (vision acuity, examination of eye fundus vessels). Then, the intake of mildly-mineralised hydrocarbonate-chloride-sodium mineral water "Obyhovskaya" directly from the spring under sanatorium conditions is administered. Water is taken in heated to a temperature of 37°C in a dose of 3 ml per 1 kg of body weight 3 times per day 40 minutes before meal, the course constitutes 18 days.

EFFECT: application of the invention makes it possible to normalise the general blood test, blood sugar, general urine analysis, improve the condition of the visual analyser and indices of the kidney blood flow.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to biotechnology. What is presented is a probiotic composition containing a probiotic ingredient, which is presented by Bifidobacterium longum R175 and one or two bacterial species specified in a group consisting of Lactobacillus rhamnosus R11, Lactobacillus helveticus R52 and Lactobacillus plantarum R1012, and a carrier composition. The above carrier composition contains mixture of prebiotics containing inulin and fructose, lactoferrin, inorganic salts, and glutathione as possible. There are also presented versions of the compositions in certain ratio of the above ingredients. What is also presented is a version of the composition containing mixture of probiotic ingredients consisting of Bifidobacterium longum R175 and Lactobacillus rhamnosus R11, a prebiotic ingredient, lacroferrin, inorganic salts and Saccharomyces boulardii. The above compositions are used for supporting and/or recovering the intestinal health and for preventing disbiosis of any origin in mammals, as well as in a method for improving a survival rate of the bacteria Bifidobacterium longum in the gastrointestinal tract.

EFFECT: group of inventions provides the effective colonisation of the gastrointestinal tract with the probiotic ingredients, causes the accompanying anti-inflammatory and immunomodulatory action.

20 cl, 4 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents pharmaceutical composition for treating gastroesophageal reflux disease, containing at least one proton pump inhibitor and at least one probiotic, wherein the proton pump inhibitor is taken in the amount of 0.05-25 wt % in the composition; and the probiotic is taken in the amount of 10-95 wt %; additive agents up to 100 wt %.

EFFECT: provided preventing Hpylori translocation, avoiding the necessity of Hpylori detection and antibacterial course of eradication, higher safety of the prolonged therapy with the proton pump inhibitors and avoided gastric mucosa atrophy, and a risk of gastric cancer.

5 cl, 10 tbl

FIELD: food industry.

SUBSTANCE: invention relates to a food composition usage in infant and children alimentation. The composition contains a sphingophospholipid, sphingomyelin or ceramide, a lysosphingophospholipid, sphingoid phosphate, sphingoid base and at least one indigestible carbohydrate. The indigestible carbohydrate may be represented by fructooligosaccharides, galactooligosaccharides, glucooligosaccharides, arabinooligosaccharides, mannan-oligosaccharides, xylooligosaccharides, fucooligosaccharides, arabinogalactooligosaccharides, glucomannooligosaccharides, galactomann oligosaccharides, sialic acid oligosaccharides and uronic acid oligosaccharides.

EFFECT: composition increases the prebiotic index and enhances the ratio of Bifidobacteria to the total bacterial mass.

11 cl, 2 tbl, 3 ex

FIELD: food industry.

SUBSTANCE: invention relates to food for infants and/or young children. The food contains indigestible oligosaccharides with polymerisation degree equal to 2 - 200, unviable Bifidobacterium breve in an amount equivalent to 103 CFU - 1013 CFU of B. breve per g of the food dry weight, and viable Bifidobacterium breve in an amount of less than 103 CFU of B. breve per g of the food dry weight. The invention relates to the food application for production of a composition for feeding infants and/or young children.

EFFECT: indigestible oligosaccharides combination combined with unlivable Bifidobacterium breve promotes prevention and/or therapy of atopic illness and food allergy.

19 cl, 2 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: declared invention refers to chemical-pharmaceutical and food industry, and concerns a food composition containing food fibres which is effective for treating or reducing rate of muscular atrophy and/or chronic muscular atrophy and/or sarcopenia, and the food fibre contain at least 30 wt % of indigestible oligosaccharides having a chain length of 3-10 monosaccharide units. Besides, the composition may contain others oligo- or polysaccharides, especially polysaccharides having a majority of anhydropyranose units.

EFFECT: composition possesses high clinical effectiveness in chronic muscular atrophy.

15 cl, 5 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine and pharmaceutical industry, namely to using mixtures of oligosaccharides, in particular, for treatment and/or prevention of symptoms selected from the group, consisting of nausea, bouts of fever and convulsions during fever.

EFFECT: production of mixtures of oligosaccharides for treatment and/or prevention of infections.

5 cl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular, to experimental cardiopharmacology, and can be used for modelling and correction of endothelial dysfunction. For this purpose in experiment endothelial dysfunction is modelled by creation of hypoestrogenic condition by bilateral ovariectomy in laboratory animal and during 6 weeks by addition into food of fructose, specific weight of which constitutes 60% of total ration, as well as by daily single irritation by electric current with 10 ms, voltage 30 V, intensity 0.66 mA, passed through electrodes, applied on animal's tail moistened with physiological solution. Degree of endothelial dysfunction development is evaluated by ratio of endothelium-independent and endothelium-dependent vasodilation, and formation of metabolic disorders by change of glycemia level by 120 minute in oral test on tolerance to glucose. Claimed model can be applied for estimation of pharmacological correction of endothelial dysfunction in reproduction of metabolic disorders.

EFFECT: method makes it possible to estimate dynamics of formation of endothelial dysfunction in modelling of metabolic disorders with application of fructose-containing diet and electric current.

1 ex, 3 tbl, 1 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine and concerns an agent reducing degree of intoxication and exhibiting anti-hungover action.

EFFECT: invention provides reduction of degree of acute alcohol intoxication (inebriation) and anti-hungover action.

6 cl, 4 ex, 4 dwg

FIELD: food industry.

SUBSTANCE: invention refers to food composition for infants. The food composition consists of a) non-digestible fermented partially hydrolysed gum with a degree of polymerisation between 10 and 300 at amount from 0.1 to 15 g per 100 g of dry weight of composition. Also the composition consists of b) non-digestible fermented soluble polysaccharide with a degree of polymerisation between 10 and 300, different, than partially hydrolysed gum, at amount from 0.1 to 15 g per 100 g of dry weight of the said composition. Notably, weight ratio of a) : b) is between 19:1 and 1:19. Caloric value of the composition is from 50 to 200 kcal/100 ml upon reduction of it to a liquid form. Additionally, protein composes from 5 to 16% of total caloric value, fat - from 35 to 60%, while carbohydrates - from 25 to 75%.

EFFECT: facilitating production of synergetic composition for feeding infants which is used in method of treatment and/or prevention of inflammatory diseases of bowels and/or syndrome of irritated bowels of infants.

15 cl, 1 dwg, 2 tbl, 4 ex

Vaginal composition // 2369389

FIELD: medicine.

SUBSTANCE: vaginal composition comprises viable microorganisms of lactobacillus and/or bifid bacteria, preferentially Lactobacillus bifidus, devitalised saccharomyces, preferentially Saccharomyces cerevisiae, saccharide(s), vitamin A retinal and zinc with specified ratio of composition components.

EFFECT: vaginal protection without negative effect or infliction of harm.

14 cl, 2 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine. What is described is a method for preparing a bioadhesive compacted matrix that involves preparing a homogenous mixture of powders containing at least one alkyl cellulose or one hydroxyalkyl and a water-insoluble, water-swelling cross-linked polycarboxyl polymer, using the same powder mixture to prepare compressed work pieces using direct extrusion and heating of the compressed work pieces prepared thereby to the temperatures within the range of 80-250°C for 1-60 minutes. The powder mixture may also contain at least one active substance.

EFFECT: compressed work pieces prepared thereby are characterised by the prolonged release and show the kinetics of the active substance release of substantially zero order in an aqueous solution at pH 4-8.

15 cl, 18 dwg, 5 tbl, 4 ex

Up!